HRS 2020: Boston Scientific’s Next-Gen LAAC Device Hits Targets In PINNACLE FLX Trial
The PINNACLE FLX trial of the next-generation WATCHMAN left atrial appendage closure device met its primary safety and effectiveness endpoints with a low adverse event rate of 0.5%.
You may also be interested in...
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the second day of the meeting.
The series C financing will support development of its CLAAS device, an alternative to anticoagulant drugs for atrial fibrillation patients.
The company’s sales declined 29% in the second quarter of 2020 due to the pandemic, but sales trends indicate the start of a worldwide recovery across all of Boston Scientific’s businesses.